IBDEI0QA ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12969,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,12969,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,12970,0)
 ;;=204.01^^87^827^1
 ;;^UTILITY(U,$J,358.3,12970,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12970,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,12970,1,5,0)
 ;;=5^ALL in Remission
 ;;^UTILITY(U,$J,358.3,12970,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,12971,0)
 ;;=204.10^^87^827^15
 ;;^UTILITY(U,$J,358.3,12971,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12971,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,12971,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,12971,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,12972,0)
 ;;=204.11^^87^827^14
 ;;^UTILITY(U,$J,358.3,12972,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12972,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,12972,1,5,0)
 ;;=5^CLL in Remission
 ;;^UTILITY(U,$J,358.3,12972,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,12973,0)
 ;;=201.90^^87^827^42
 ;;^UTILITY(U,$J,358.3,12973,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12973,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,12973,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,12973,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,12974,0)
 ;;=200.20^^87^827^46
 ;;^UTILITY(U,$J,358.3,12974,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12974,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,12974,1,5,0)
 ;;=5^Lymphoma, Burkitt's, Unspecified Sites
 ;;^UTILITY(U,$J,358.3,12974,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,12975,0)
 ;;=202.00^^87^827^48
 ;;^UTILITY(U,$J,358.3,12975,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12975,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,12975,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,12975,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,12976,0)
 ;;=200.10^^87^827^47
 ;;^UTILITY(U,$J,358.3,12976,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12976,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,12976,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,12976,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,12977,0)
 ;;=203.00^^87^827^59
 ;;^UTILITY(U,$J,358.3,12977,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12977,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,12977,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,12977,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,12978,0)
 ;;=203.01^^87^827^58
 ;;^UTILITY(U,$J,358.3,12978,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12978,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,12978,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,12978,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,12979,0)
 ;;=238.6^^87^827^60
 ;;^UTILITY(U,$J,358.3,12979,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12979,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,12979,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,12979,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,12980,0)
 ;;=205.00^^87^827^4
 ;;^UTILITY(U,$J,358.3,12980,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12980,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,12980,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,12980,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,12981,0)
 ;;=205.01^^87^827^3
 ;;^UTILITY(U,$J,358.3,12981,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12981,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,12981,1,5,0)
 ;;=5^AML in Remission
 ;;^UTILITY(U,$J,358.3,12981,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,12982,0)
 ;;=205.10^^87^827^17
 ;;^UTILITY(U,$J,358.3,12982,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,12982,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,12982,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,12982,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,12983,0)
 ;;=205.11^^87^827^16
